Glaukos Co. (NYSE:GKOS)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $79.95, but opened at $83.15. Glaukos shares last traded at $83.42, with a volume of 515 shares.
Several brokerages have recently commented on GKOS. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised Glaukos from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $50.00 to $72.00 in a research note on Wednesday, December 16th. Oppenheimer raised Glaukos from a “market perform” rating to an “outperform” rating and set a $100.00 price objective for the company in a research note on Thursday. Smith Barney Citigroup raised Glaukos from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $50.00 to $72.00 in a research note on Wednesday, December 16th. Finally, Piper Sandler downgraded Glaukos from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $70.00 to $80.00 in a research note on Friday, January 29th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. Glaukos has an average rating of “Hold” and an average target price of $66.38.
The company has a market capitalization of $3.82 billion, a P/E ratio of -48.45 and a beta of 1.87. The company has a debt-to-equity ratio of 0.37, a current ratio of 9.73 and a quick ratio of 9.31. The firm has a fifty day moving average price of $88.10 and a 200-day moving average price of $72.06.
In other Glaukos news, CFO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction on Monday, March 15th. The stock was sold at an average price of $87.88, for a total transaction of $439,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.70% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. US Bancorp DE grew its holdings in Glaukos by 137.9% during the third quarter. US Bancorp DE now owns 590 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 342 shares during the period. Strs Ohio grew its holdings in Glaukos by 900.0% during the third quarter. Strs Ohio now owns 1,000 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 900 shares during the period. Marshall Wace North America L.P. bought a new position in Glaukos during the first quarter valued at $55,000. Vantage Consulting Group Inc bought a new position in Glaukos during the fourth quarter valued at $74,000. Finally, KBC Group NV bought a new position in shares of Glaukos in the fourth quarter worth $102,000.
Glaukos Company Profile (NYSE:GKOS)
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Article: How is diluted EPS different from basic EPS?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.